Breast Cancer Pulse #2
$599.00
Breast Cancer Pulse #2
$599.00
Publisher: Biomedtracker
Published:
May 2015
Number of pages:
16
Formats:
PDF
- Description
- Samples
We performed a 5-question survey of 24 oncologists in the US to gauge current prescribing practices for breast cancer treatments, with a focus on HR+/HER2- recurrent or metastatic breast cancer. Drugs and drug candidates discussed:
•Neratinib, PBYI
•Herceptin (trastuzumab), Roche
•Perjeta (pertuzumab), Roche
•Kadcyla (trastuzumab-DM1), Roche
•Tykerb (lapatinib), GSK
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Breast Cancer Pulse #1 
Sign up to the